Skip to main content
Article thumbnail
Location of Repository

Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports

By R Andrew Moore, Sheena Derry and Henry J McQuay
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. A users guide to measurement in medicine. Osteoarthritis Cartilage 2006, 14(suppl A):A10-A13.
  2. (1999). A: Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks nonsteroidal anti-inflammatory drug trial. Rheumatology
  3. (2002). Adult Treatment Panel III: Third report on National Cholesterol Education Program expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report: IX adherence. Circulation
  4. (2002). Altman D: Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice.
  5. Calculating confidence intervals for relative risk (odds ratios) and standardised ratios and rates.
  6. (2006). Canadian Hypertension Education Program Outcomes Research Task Force: The impact of the Canadian Hypertension Education Program on antihypertension prescribing trends. Hypertension
  7. (1999). DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet
  8. (2006). DM: Different methods of presenting risk information and their influence on medication compliance intentions: results of three studies. Clin Ther
  9. (1999). Doering PL: Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis. Pharmacotherapy
  10. (2008). Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharmacol.
  11. (1995). Hansten PD: Nonsteroidal anti-inflammatory drug discontinuation in patients with osteoarthritis.
  12. (2005). HJ: Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain
  13. (2000). HJ: An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain
  14. (1996). HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials
  15. (2004). HJ: Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised trials. Pain
  16. (2006). HJ: Nonsteroidal antiinflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord
  17. (2005). HJ: Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther
  18. (2005). HJ: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from clinical trial reports. Arthritis Res Ther
  19. (2005). Hoffman BB: Improving adherence to guidelines for hypertension drug prescribing: cluster randomised controlled trial of general versus patient-specific recommendations.
  20. (1999). Implanon: a review of clinical studies.
  21. (2007). JM: All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis.
  22. (2005). Kisoensingh SU: Initial phase of chronic medication use: patients' reasons for discontinuation. Br J Clin Pharmacol.
  23. (2005). LC: Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int Clin Psychopharmacol
  24. (2000). LF: Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis.
  25. (2000). Liu JLY: Misleading funnel plot for detection of bias in meta-analysis.
  26. (2001). Nalysnyk L: Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy
  27. (2000). Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature.
  28. (2004). RC: Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation
  29. (2007). Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review.
  30. (2001). Reporting of adverse drug reactions in randomised controlled trials – a systematic survey.
  31. (2001). Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. Ann Rheum Dis.
  32. (2004). RW: Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf
  33. (1995). Sackett DL: The number needed to treat: a clinically useful measure of treatment effect.
  34. (1994). Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol
  35. (2001). Shadforth MF: Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM
  36. (1997). Single-patient data meta-analysis of 3,453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain
  37. (2004). SZ: Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
  38. (2000). Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain
  39. (2002). The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology
  40. (2004). TM: Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.